Navigation Links
InterCure Announces 100,000th RESPeRATE Unit Sold
Date:1/24/2008

class consumer healthcare team to successfully launch into the retail market. This combination of momentum and expertise gives us great confidence as we head into a time of rapid acceleration in 2008."

About RESPeRATE

RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically proven to lower blood pressure through paced breathing therapy. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.

About InterCure, Ltd.

InterCure, a medical device company, publicly traded on the Tel Aviv Stock Exchange (TASE: INCR) has become a leader in the growing Personal Therapeutic Device category. Its broadly patented "device-guided breathing" technology platform enables a systematic reduction in sympathetic outflow of the autonomic nervous system. InterCure is successfully selling the world's first hypertension treatment device, RESPeRATE(R), with more than 100,000 units sold. With multiple published clinical studies, regulatory clearance in most key international markets (including FDA over-the-counter ("OTC") clearance in the U.S., the European CE mark and the Chinese SDA among others) and a renowned scientific advisory board, RESPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension. (http://www.intercure.com)

Forward-Looking Statements

This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking
'/>"/>

SOURCE InterCure, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
2. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
3. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
4. iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product
5. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
6. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
7. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
8. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
9. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- According to a new market research ... Device, Display, & Microprocessor/MCU), by Application (Imaging, Medical Therapeutics, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... reach $56.50 Billion by 2020, growing at a CAGR ... 235 market data Tables and 71 Figures spread through ...
(Date:9/17/2014)... , Sept. 17, 2014  NuView Life ... global licensing and collaboration agreement with Otsuka Pharmaceutical ... NuView,s investigative genomic-based diagnostic biomarker to detect cancers ... includes all other future diagnostic-imaging applications. NuView retains ... therapeutic delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... , Sept. 17, 2014 Isis ... that it has earned a $4 million milestone ... ) associated with the initiation of a Phase ... multi-drug resistant (MDR), gram-negative bacterial infections.  The Phase ... to evaluate the efficacy and safety of plazomicin ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
(Date:9/18/2014)... (PRWEB) September 18, 2014 Specialty ... in Westlake, OH, announces that they have achieved ... PowerServer, a Complete Certified Ambulatory EHR-certified system developed ... Specialty Teleradiology had a non MU compliant PACS ... their business grew from a niche in oncology ...
(Date:9/18/2014)... Doylestown, PA (PRWEB) September 18, 2014 ... month by successfully launching its first product a mere ... F PRIME™ is a high performance glycan release enzyme ... assurance, glycobiology research, and the basis for tissue pathology ... Bulldog Bio (Portsmouth, NH) for the North American market ...
(Date:9/18/2014)... 9Lover.com, an internationally well-known designer and leader in ... promotion for its maternity wedding outfits. Now, all the ... maternity wedding dresses on its website. , ... consumers. The company’s development manager believes the cheap maternity ... The current special offer will last until September 29, ...
(Date:9/17/2014)... 2014 Today, Fecbek, a leading dress manufacturer ... special occasion gowns. These are a lot of beautiful A-line ... new range. , A skirt is a tube- or ... or part of the legs. In the western world, skirts ... be a draped garment which is made out of a ...
(Date:9/17/2014)... Recently, UWDress.com, an innovative company that ... occasion outfits, has released its 2014 empire waist ... has launched a big sale for these new and ... deeply discounted rates, from 15 to 65 percent off. ... on using comfortable to wear materials. Its elegant items ...
Breaking Medicine News(10 mins):Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 2Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 3Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2Health News:Fecbek.com Has Recently Announced Its New Series of Delicate Special Occasion Gowns Online 2Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2
... Sweden: Two trials presented at the Heart Failure Congress 2011, ... European Society of Cardiology (HFA of the ESC), will help ... heart failure (CHF) in whom telemedical management delivers benefits. ... Late Breaking Session 1 - revealed that telemonitoring showed significant ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, ... benefits of robotic surgery on their websites without solid ... researchers report. In fact, four out of 10 ... robotic surgery is better than conventional surgery, an assertion ...
... May 21 (HealthDay News) -- As summer approaches and ... experts say. "We are not invincible when it ... an athletic trainer with the University of Tennessee at ... Medical and Science Advisory Board, in a news release ...
... chemotherapy is used to kill cancer cells, it can also ... bone marrow and blood cells, often limiting the ability to ... Cancer Research Center reported at today,s annual meeting of the ... one possible approach to reduce this toxic effect on bone ...
... York, NY (May 20, 2011)The American Federation for Aging Research ... 83 advanced fellows and junior faculty at 27 Centers of ... This effort, funded with support from the John A. Hartford ... create the cadre of academic leaders in geriatrics. As our ...
... , FRIDAY, May 20 (HealthDay News) -- Treating chronic ... and function, according to a new study. Prior research ... problems and reduced gray matter in brain areas that play ... pain, such as anxiety and depression. But it wasn,t clear ...
Cached Medicine News:Health News:Telemonitoring can improve overall survival of HF patients 2Health News:Telemonitoring can improve overall survival of HF patients 3Health News:Telemonitoring can improve overall survival of HF patients 4Health News:Telemonitoring can improve overall survival of HF patients 5Health News:Robotic Surgery Oversold on Hospital Websites, Study Contends 2Health News:Robotic Surgery Oversold on Hospital Websites, Study Contends 3Health News:Robotic Surgery Oversold on Hospital Websites, Study Contends 4Health News:Keeping Cool in the Heat 2Health News:Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy 2Health News:AFAR announces the 2011 Hartford Scholars in Geriatric Medicine 2
100cc silicone evacuator with hubless flat drain and trocar...
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Silicone Flat Hubless Drains...
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
Medicine Products: